Skip to main content
GENFIT logo

GENFIT — Investor Relations & Filings

Ticker · GNFT ISIN · FR0004163111 LEI · 969500XPWN2DMZQA5X73 PA Professional, scientific and technical activities
Open in API
Filings indexed 681 across all filing types
Latest filing 2020-11-16 Capital/Financing Update
Country FR France
Listing PA GNFT

About GENFIT

https://www.genfit.com

GENFIT is a biopharmaceutical company dedicated to developing therapeutic and diagnostic solutions for patients with rare and severe liver diseases characterized by high unmet medical needs. The company's primary focus is on Acute-on-Chronic Liver Failure (ACLF) and its associated conditions, such as acute decompensation (AD) and hepatic encephalopathy (HE). Leveraging a scientific heritage of over two decades, GENFIT is a pioneer in liver disease research and development, aiming to improve the lives of patients with these life-threatening conditions.

Recent filings

Filing Released Lang Actions
GENFIT : Information financière du troisième trimestre 2020 et lancement de la renégociation de la dette obligataire
Capital/Financing Update Classification · 99% confidence The document is titled "GENFIT : Information financière du troisième trimestre 2020 et lancement de la renégociation de la dette obligataire" (GENFIT: Third Quarter 2020 Financial Information and Launch of Bond Debt Renegotiation). It explicitly provides key financial figures for the first nine months of 2020 and the cash position as of September 30, 2020, noting that the data is established according to IFRS standards. This content strongly indicates a periodic financial report covering a period shorter than a full year (Q3 results). This aligns with the definition of an Interim / Quarterly Report (IR). Although it also discusses debt renegotiation, the primary focus and structure revolve around the quarterly financial update. It is not merely an announcement of a report (RPA) as it contains the actual financial data.
2020-11-16 French
rapport semestriel 2020
Interim / Quarterly Report Classification · 100% confidence The document is titled 'RAPPORT D'ACTIVITE ET FINANCIER SEMESTRIEL AU 30 JUIN 2020' (Half-Year Activity and Financial Report as of June 30, 2020). It contains a detailed summary, consolidated financial statements, and an audit report for the interim period. It is a comprehensive financial report for a period shorter than a full fiscal year, fitting the definition of an Interim/Quarterly Report (IR). H2 2020
2020-09-30 French
GENFIT: First Half-Year 2020 Financial Report and New Corporate Strategy
Earnings Release Classification · 99% confidence The document is explicitly titled "GENFIT: First Half-Year 2020 Financial Report and New Corporate Strategy" and contains detailed condensed consolidated financial statements (Statement of Operations) for the six-month period ended June 30, 2020. This structure, covering a period shorter than a full year with comprehensive financial details, aligns perfectly with the definition of an Interim/Quarterly Report. Although it mentions filing with the AMF and refers to the 20-F (Annual Report), the core content presented here is the half-year financial performance and business update, making 'Interim / Quarterly Report' (IR) the most accurate classification. It is not merely an announcement of a report (RPA) because the full financial tables and detailed management discussion are included in the text provided. H1 2020
2020-09-30 English
GENFIT présente ses résultats financiers du premier semestre 2020 et sa nouvelle stratégie
Earnings Release Classification · 99% confidence The document is titled 'GENFIT présente ses résultats financiers du premier semestre 2020' (GENFIT presents its financial results for the first half of 2020). It contains detailed financial figures (cash position, operating expenses, net loss) for the six-month period ending June 30, 2020, including an IFRS summary table comparing H1 2020 to H1 2019. The text explicitly mentions that the 'rapport semestriel d'activité et financier' (half-yearly activity and financial report) has been filed. This content structure—a press release summarizing detailed financial performance for a period shorter than a year—is characteristic of an Interim/Quarterly Report (IR). It is not the full 10-K (Annual Report), nor is it just an Earnings Release (ER) which typically contains only key highlights without the detailed financial tables provided here. The length (69,861 chars) suggests a comprehensive document, not just a short announcement (RPA/RNS). H1 2020
2020-09-30 French
GENFIT et LabCorp signent un accord exclusif pour la commercialisation d’un nouvel outil de diagnostic de la NASH
Regulatory Filings Classification · 95% confidence The document is a press release dated September 28, 2020, announcing an exclusive licensing agreement between GENFIT and LabCorp for the commercialization of the NIS4™ diagnostic test for NASH in the US and Canada. This type of announcement, detailing a significant business partnership, licensing deal, or strategic development, does not fit the definitions for standard periodic financial reports (10-K, IR, ER, MRQ) or specific corporate actions (DIV, SHA, POS). It is a general corporate announcement regarding a strategic transaction. Since it is a formal press release announcing a major business development rather than a regulatory filing fallback (RNS) or a report publication announcement (RPA), the most appropriate category for a significant business/strategic announcement that isn't explicitly covered elsewhere is often treated as a general regulatory filing or a specific strategic update. Given the options, this is a strategic business announcement. It is not a proxy statement (DEF 14A/PSI), an earnings release (ER), or a management discussion (MDA). It is most closely aligned with a general corporate announcement, which often defaults to RNS if no other specific category fits. However, since it details a major commercial/licensing agreement, it is a significant corporate event announcement. In the context of the provided definitions, 'RNS' (Regulatory Filings - General regulatory announcements and fallback category for miscellaneous filings) is the best fit for a press release detailing a strategic partnership that doesn't match the other specific financial or governance codes.
2020-09-28 French
GENFIT and LabCorp Sign Exclusive Agreement to Commercialize a Novel Diagnostic Test for Liver Disease
Regulatory Filings Classification · 97% confidence The document is a press release dated September 28, 2020, announcing an exclusive licensing agreement between GENFIT and LabCorp regarding a diagnostic test for NASH. It details the terms of the agreement, the technology involved (NIS4™), and quotes executives from both companies. This type of announcement, which details a significant business development (a licensing/commercialization deal) but is not a formal regulatory filing like a 10-K, earnings release, or dividend notice, fits best under the category of a general business update or announcement. Since there is no specific category for 'Licensing Agreement' or 'Partnership Announcement', and it is not a formal financial report, it should be classified as a general Regulatory Filing/Announcement (RNS) or potentially a Capital/Financing Update (CAP) if the deal involved significant upfront payments, but given the content focuses on a commercial partnership rather than fundraising or capital structure change, RNS is the most appropriate fallback for a press release detailing a strategic business event.
2020-09-28 English

Browse filings by year

14 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.